Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Down 71.7% in February

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 147,400 shares, a decline of 71.7% from the February 13th total of 520,300 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is presently 0.1 days.

Inspira Technologies Oxy B.H.N. Price Performance

Shares of NASDAQ IINN traded down $0.06 during mid-day trading on Thursday, hitting $0.71. 185,184 shares of the company traded hands, compared to its average volume of 1,444,482. The company has a current ratio of 2.23, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09. Inspira Technologies Oxy B.H.N. has a 1 year low of $0.65 and a 1 year high of $2.45. The business has a 50 day moving average of $0.93 and a two-hundred day moving average of $1.14.

Hedge Funds Weigh In On Inspira Technologies Oxy B.H.N.

An institutional investor recently raised its position in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC raised its position in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 142.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,622 shares of the company’s stock after purchasing an additional 21,532 shares during the quarter. Renaissance Technologies LLC owned approximately 0.29% of Inspira Technologies Oxy B.H.N. worth $37,000 at the end of the most recent quarter. Institutional investors own 12.72% of the company’s stock.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.